tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

CMMB Stock Latest News

Chemomab: Publications ‘reinforce’ potential of I CCL24 antibody for PSC
The FlyChemomab: Publications ‘reinforce’ potential of I CCL24 antibody for PSC
1M ago
CMMB
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
PremiumPress Releases
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
1M ago
CMMB
Chemomab Shareholders Approve Key Resolutions
PremiumCompany Announcements
Chemomab Shareholders Approve Key Resolutions
1M ago
6K
CMMB
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
PremiumPress Releases
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
2M ago
CMMB
Chemomab Therapeutics presents data on clinical potential of CM-101
PremiumThe Fly
Chemomab Therapeutics presents data on clinical potential of CM-101
2M ago
CMMB
Chemomab Therapeutics management to meet virtually with Roth MKM
PremiumThe FlyChemomab Therapeutics management to meet virtually with Roth MKM
2M ago
CMMB
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
PremiumPress Releases
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
2M ago
CMMB
Chemomab Therapeutics initiated with a Buy at Maxim
PremiumThe Fly
Chemomab Therapeutics initiated with a Buy at Maxim
2M ago
CMMB
Chemomab Therapeutics initiated with a Buy at Maxim
PremiumThe Fly
Chemomab Therapeutics initiated with a Buy at Maxim
2M ago
CMMB
Chemomab Advances PSC Trial with Promising Outlook
PremiumCompany Announcements
Chemomab Advances PSC Trial with Promising Outlook
3M ago
6K
CMMB
Chemomab Therapeutics reports Q1 EPS (1c) vs. (4c) last year
PremiumThe Fly
Chemomab Therapeutics reports Q1 EPS (1c) vs. (4c) last year
3M ago
CMMB
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
PremiumPress Releases
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
3M ago
CMMB
Chemomab Therapeutics Receives Nasdaq Extension
PremiumCompany AnnouncementsChemomab Therapeutics Receives Nasdaq Extension
3M ago
6K
CMMB
Chemomab Therapeutics granted 180-day extension to regain Nasdaq compliance
PremiumThe Fly
Chemomab Therapeutics granted 180-day extension to regain Nasdaq compliance
3M ago
CMMB
Chemomab Therapeutics upgraded to Outperform from Perform at Oppenheimer
PremiumThe Fly
Chemomab Therapeutics upgraded to Outperform from Perform at Oppenheimer
3M ago
CMMB
Chemomab Annual Meeting and Key Proposals
PremiumCompany Announcements
Chemomab Annual Meeting and Key Proposals
3M ago
6K
CMMB
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
PremiumPress Releases
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
3M ago
CMMB
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
PremiumPress Releases
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
3M ago
CMMB
Chemomab Therapeutics reports publication on its CCL24 target, SSc
PremiumThe Fly
Chemomab Therapeutics reports publication on its CCL24 target, SSc
3M ago
CMMB
Chemomab Therapeutics to hold a conference call
PremiumThe FlyChemomab Therapeutics to hold a conference call
3M ago
CMMB
Chemomab Therapeutics to hold a conference call
PremiumThe Fly
Chemomab Therapeutics to hold a conference call
3M ago
CMMB
Chemomab Therapeutics to hold a conference call
PremiumThe Fly
Chemomab Therapeutics to hold a conference call
4M ago
CMMB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >